🔗 Share this article

Given that the United States proceeds with historic adjustments to its immunization guidelines, one figure has surfaced unexpectedly: Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccines in the pandemic and has concentrated on potential deaths after COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Schedule

Public health authorities had intended to reveal radical changes to the pediatric vaccine schedule recently, synchronizing the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of step with much of the global community with little proof for public health gain. The planned update has been postponed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this year.

A New Direction at the Agency

The acting appointment could signify a tighter collaboration between the drug and biologics branches as Høeg and Dr. Prasad consolidate power at the agency – and it suggests a increased emphasis upon dismantling previously authorized immunizations at the FDA.

Høeg has often pushed for halting specific pediatric shot schedules in the US to become more similar to Denmark's approach, a country with universal health coverage and a population about the size of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – traditionally the purview of Prasad, director of the FDA’s CBER – instead of drug regulation.

Concerns Over Qualifications

The appointee has no apparent experience in medication creation, approval processes or management, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have the requisite experience” for running the CDER, remarked Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former directors of CBER would “grasp regulatory frameworks and the underlying principles of medication creation”, commented Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who led CBER have had.”

CDER has an immense portfolio at the agency, Woodcock pointed out.

“Many people just pays attention on the innovative therapies, but the generic drug division clears a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and so forth, and each of these must be looked after,” Woodcock explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative aspect to the job, which oversees more than 5,000 staff members. “It’s a enormous leadership role, if you execute it properly,” Woodcock concluded.

Response and Disputed Initiatives

Regarding inquiries about Høeg’s qualifications and whether this assignment indicates more teamwork among FDA leaders on vaccines, a spokesperson responded that the “inquiries rely on incorrect assumptions”.

“This background is consistent with the functions of her job,” the spokesperson stated, noting the time Høeg spent counseling the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s controversial expedited review system, a contentious rapid therapy clearance system that reportedly worried her former heads. “By what process are these medications being chosen for this voucher program? Who makes the decisions?” Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he said, “the agency seems to be moving towards laxer rules of most medications, except for shots.”

Public History on Vaccines

Concerning vaccines, Høeg has a more documented, if troubling, track record, some experts said. She published a study using unconfirmed public submissions to determine the rate of myocarditis following Covid immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the incoming administration included altering regulations for novel immunizations and discontinuing “non-essential” immunizations, she stated post-election on a audio program. At the agency, Høeg has allegedly floated the idea of barring adolescent males from getting Covid vaccinations.

“She’s an complete true believer who begins with her conclusions and tailors the evidence to accommodate the data in a highly deceptive, fraudulent way,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg aligned with other contrarians, {like|